Clinical Trials on Macula; Degeneration in Germany

Total 356 results

Bayer

Recruiting

The SPECTRUM Study: An Observational Study to Learn More About How Well Aflibercept 8 mg Works in Treating Visual Impairment Due to Neovascular Age-related Macular Degeneration or Diabetic Macula Edema

Visual Impairment | Neovascular Age-related Macular Degeneration (nAMD) | Diabetic Macula Edema (DME)

Germany, Canada, Denmark, France, Italy, Saudi Arabia, Switzerland, Australia, Finland, Netherlands, Sweden, Norway, United Arab Emirates, Japan, United Kingdom
Johannes Gutenberg University Mainz
Novartis

Completed

Functional and Structural Outcomes in Neovascular Age-related Macular Degeneration (CAPTAIN)

Neovascular Age-related Macular Degeneration

Germany
Apheresis Research Institute

Completed

Dry Age-Related Macular Degeneration (AMD) Treatment With Rheopheresis Trial (ART)

Dry Age Related Macular Degeneration

Germany
Klinikum Chemnitz gGmbH

Completed

Surgical Outcome of Macular Membrane Peeling Associated With Significant Macular Drusen

Age Related Macular Degeneration | Epiretinal Membrane | Macular Holes

Germany
University of Luebeck

Completed

Ranibizumab Short- and Log-term Effects on Retinal Function in wAMD (LucERG)

Age-Related Macular Degeneration | Retinal Function

Germany
University of Luebeck

Completed

Treatment of Diabetic Macular Edema With 0.5mg Intraocular Ranibizumab (Lucentis)

Age-Related Macular Degeneration

Germany
University of Jena

Completed

Effects of Xanthophylls on Optical Density

Age-Related Macular Degeneration

Germany
Bayer
Regeneron Pharmaceuticals

Completed

Investigating the Effectiveness of Eylea in Patients With Wet Age-related Macular Degeneration (PERSEUS)

Wet Age-related Macular Degeneration

Germany
Johann Wolfgang Goethe University Hospital

Completed

Combined Therapy in Age-Related Macular Degeneration (ARMD)

Age-Related Macular Degeneration

Germany
Bayer

Completed

Non-Persistence/Non-Adherence (NP/NA) in Wet Age-related Macular Degeneration (wAMD) Patients in Germany

Wet Macular Degeneration

Germany
National Eye Institute (NEI)

Completed

AMD Phenotype and Genotype Study

Age-Related Macular Degeneration | AMD

United States, Germany
Klinikum Ludwigshafen
Pfizer

Unknown

Subretinal Macugen® for Neovascular Age-Related Macular Degeneration

Age-related Macular Degeneration

Germany
Bayer

Completed

A Follow-up Physician Survey to Evaluate Physician Knowledge of Safety and Safe Use Information for Aflibercept Administered by Intravitreal Injection in Europe

Ophthalmology, Macular Degeneration

Germany
Novartis Pharmaceuticals

Completed

Systemic Vascular Endothelial Growth Factor (VEGF) Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Neovascular Age-related Macular Degeneration (TIDE AMD)

Wet Age-Related Macular Degeneration

Germany
University Hospital Tuebingen

Completed

Assessment of Psychological Strain and Perioperative Fear in Intravitreal Injections (FIVA)

Stress | Age-related Macular Degeneration

Germany
Klinikum Bremen-Mitte, gGmbH
Kompetenzzentrum für Klinische Studien, Bremen

Unknown

Prevention of Vision Loss in Patients With Age-Related Macular Degeneration (AMD) by Intravitreal Injection of Bevacizumab and Ranibizumab (VIBERA)

Age-Related Neovascular Macular Degeneration

Germany
University Hospital, Bonn

Completed

Ranibizumab In Pigment Epithelium Tears Secondary To Age-Related Macular Degeneration Study (RIP)

Age Related Macular Degeneration

Germany
University Hospital Muenster

Unknown

Reticular Pseudodrusen Progression Study

Age-related Macular Degeneration

Germany
Newtricious R&D BV
Sprim Advanced Life Sciences

Completed

Intervention Trial in Early Age-related Macular Degeneration (I-TEAM)

Age-related Macular Degeneration (AMD)

United States, Germany, Netherlands, United Kingdom
University Hospital, Bonn

Completed

Directional Spread in Geographic Atrophy (DSGA)

Nonexudative Age-related Macular Degeneration

Germany
Novartis Pharmaceuticals

Completed

A Non-interventional Study to Assess the Influence of Automated Optical Coherence Tomography Image Enrichment With Segmentation Information on Disease Activity Assessment in Patients Treated With Licensed Anti- VEGF Injections (RAZORBILL)

Neovascular Age-Related Macular Degeneration

Spain, Italy, Germany, Canada, Ireland
GWT-TUD GmbH
Novartis

Unknown

Combination of Standard Lucentis Therapy With Micropulse Diode Laser for the Treatment of Diabetic Macular Edema (ReCaLL)

Diabetic Macular Edema

Germany
University of Regensburg
Dr. Werner Jackstaedt Foundation

Unknown

Selective RPE Laser Treatment (SRT) for Various Macular Diseases

Age-Related Macular Degeneration | Central Serous Chorioretinopathy | Diabetic Maculopathy

Germany
Alimera Sciences

Terminated

Observational Study to Assess the Effect of Iluvien® in DME Patients Insufficiently Responsive to Available Therapies (ILUMINATE)

Diabetic Macular Edema (DME)

Germany
Boehringer Ingelheim

Completed

A 4 Week Study With BI 144807 in Patients >= 50 Years With Wet Age Related Macular Degeneration

Wet Macular Degeneration

Austria, Germany, Hungary
Bayer

Completed

Study to Assess the Effectiveness of Existing Anti vascUlar Endothelial Growth Factor (Anti VEGF) in Patients With Wet Age-related Macular Degeneration (wAMD) (AURA) (AURA)

Ophthalmology, Macular Degeneration

Japan, France, Germany, Australia, Italy, United Kingdom, Venezuela, Ireland, Netherlands, Canada
LumiThera, Inc.

Completed

Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITE II)

Dry Age-related Macular Degeneration

United Kingdom, Spain, France, Germany, Italy
University Hospital, Bonn

Completed

Fundus Autofluorescence Imaging in Age-related Macular Degeneration Using Confocal Scanning Laser Ophthalmoscopy

Age-related Macular Degeneration

Germany
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular Degeneration (FALCON)

Age-related Macular Degeneration

Germany, Switzerland
VisionCare, Inc.

Recruiting

Post-market Clinical Investigation of the SING IMT System, Model NG SI IMT 3X in Patients With End-stage Age-related Macular Degeneration

Age-Related Macular Degeneration | AMD

Italy, Ireland, Spain, Germany, United Kingdom
Bayer

Completed

Aflibercept Injection Into the Vitreous Body of the Eye: Study to Learn More About Patient Relevant Outcomes, Real World Treatment Patterns and How Well the Treatment Works for Patients Suffering From Abnormal Growth of New Blood Vessels Under the Retina. (ANDROMEDA)

Macular Degeneration

Germany
Bayer

Completed

An Integrated Analysis of the Effectiveness of Intravitreal (IVT) Aflibercept (Eylea) in Routine Clinical Practice Based on Two Large Observational Studies (GALAXY)

Macular Degeneration

Germany
University of Cologne

Unknown

Genetics in Non-response to Anti-VEGF Treatment in Exudative AMD (RESPONSE)

Macular Degeneration

Germany
Frank G. Holz
Radboud University Medical Center; Bayer; Hoffmann-La Roche; Novartis Pharmaceuticals and other collaborators

Active, not recruiting

Development of Novel Clinical Endpoints in Intermediate AMD (MACUSTAR)

Age Related Macular Degeneration (AMD)

Germany, Italy, Netherlands, United Kingdom, France, Portugal, Denmark
Alkahest, Inc.

Completed

A Study to Assess the Efficacy and Safety of AKST4290 With Aflibercept in Patients With Newly Diagnosed nAMD (PHTHALO-205)

Neovascular Age-related Macular Degeneration

United States, Germany, Poland, Hungary
University Hospital, Bonn
Genentech, Inc.

Completed

Sparing of the Fovea in Geographic Atrophy Progression (SIGHT)

Eye Diseases | Age-related Macular Degeneration | Geographic Atrophy | Atrophy

Germany
Ludwig-Maximilians - University of Munich
Allergan

Completed

Dexamethasone-Implant for the Treatment of Macula Edema Due to Irvine Gass Syndrome

Macular Edema | Visual Acuity

Germany
Allergan

Completed

A Retrospective Data Collection Study in Patients Receiving Dexamethasone Intravitreal Implant (Ozurdex®) for Macular Oedema Due to Retinal Vein Occlusion (RVO)

Macular Edema

Germany
GWT-TUD GmbH
Novartis

Completed

Intra-individual Variability and Circadian Rhythm of VEGF Levels and Interaction With Biomarkers

Diabetic Macular Edema

Germany
Boehringer Ingelheim

Completed

A Study to Test Different Doses of BI 836880 in Patients With an Eye Disease Called Wet Age-related Macular Degeneration (wAMD)

Wet Macular Degeneration

United Kingdom, United States, Germany
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Switching From Aflibercept to Ranibizumab in Patients With nAMD (SAFARI)

Neovascular Age-related Macular Degeneration

Germany, United Kingdom
Allergan

Completed

Evaluation of AGN-150998 in Exudative Age-related Macular Degeneration (AMD)

Age-related Macular Degeneration

United States, Italy, Australia, Israel, Germany, Austria, France, Switzerland
Bayer
RTI Health Solutions

Completed

Evaluation of Physician and Patient Knowledge of Safety and Safe Use Information for Aflibercept

Macular Degeneration

France, Germany, Spain, Italy, United Kingdom
Institut fuer anwendungsorientierte Forschung und...
Novartis Pharmaceuticals; University Medical Center Goettingen

Completed

Efficacy Study of Ranibizumab on Patients With Age-related Macular Degeneration. (RABIMO)

Macular Degeneration

Germany
UCB Pharma

Terminated

Alprostadil in Maculopathy Study (AIMS)

Macular Degeneration

Germany
Prof. Dr. Antonia M. Joussen
Charite University, Berlin, Germany

Terminated

Influence of Diabetes Control on Treatment of Diabetic Macular Edema With Ranibizumab (DORO)

Macular Edema, Cystoid | Visual Acuity Reduced Transiently

Germany
University of Jena

Completed

Long Term Effects of Lutein/Zeaxanthin and Omega-3- Supplementation on Optical Density of AMD Patients (LUTEGA) (LUTEGA)

Age Related Maculopathy

Germany
St. Franziskus Hospital

Withdrawn

Autofluorescence in Uveitic and Diabetic Macular Edema

Uveitis | Macular Edema

Germany
Hoffmann-La Roche

Recruiting

A Study of the Efficacy, Safety, and Pharmacokinetics of A 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)

Neovascular Age-related Macular Degeneration (nAMD)

Belgium, Korea, Republic of, Germany, Spain, United Kingdom, Australia, Italy, Argentina, Israel, Austria, Brazil, France, Singapore, Switzerland, Taiwan, Turkey
Hoffmann-La Roche

Recruiting

Extension Study for the Port Delivery System With Ranibizumab (Portal) (Portal)

Neovascular Age-Related Macular Degeneration

Belgium, United States, United Kingdom, Italy, Argentina, Spain, Israel, Australia, Austria, Brazil, Germany, Switzerland, Taiwan, France

Clinical Trials on Macula; Degeneration in Germany

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Estonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations